lasting antibody response can be obtained by a preparation which is devoid either of pyrogenic or of local irritative effects, will it be worth while attempting to immunize other than special groups of the population. Even then it may well be more rewarding to attempt to reduce the susceptibility of the childhood and teenage sector of the population, than to attempt to bolster up the waning immunity of adult workers. It is perhaps in the latter that a combination of chemoprophylaxis and periodic inoculation may ultimately offer the best hope of success. Even so, chemoprophylaxis would be limited to the period of actual occurrence of an outbreak in order to avoid useless administration and possible harmful effects of the drug.
For the present, the surveillance of influenza outbreaks on a world-wide scale, the isolation and serological analysis of viruses recovered from all over the world and the matching of influenza vaccine for small-scale use by substitution of new strains when this is desirable, must continue. Influenza is a treacherous disease with a great capacity to surprise and to shock. Influenza vaccine has not so much been tried and failed but has never really been tried at all. The time is not ripe to exploit vaccine merely to reduce absenteeism in industry when influenza virus infection is not the chief enemy. Should better vaccines become available, the way will then open for the development of a proper plan for immunization against influenza and probably against other respiratory virus infections as well. Although the natural history of influenza is complex it has two main elements which exert a special influence on its control by vaccination. The first of these is the adventat long intervalsof a new virus variant, against which the world's population has no immunity, and the consequent occurrence of pandemics. The second are the subsequent epidemics which, following the pandemic, occur every few years.
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Three groups in the population are potentially at risk in such biennial or triennial epidemics. The first is the group infected by the new strain during the pandemic but whose immunity has waned to a point where they have again become susceptible. The second group consists of those who have been infected during the pandemic and made resistant to this strain but who are later re-exposed to an influenza virus of a different antigenic pattern. The third group are those not infected and who are thus still susceptible.
On the whole it appears that the third group is likely to be the largest; the epidemics which occur in the years following a pandemic probably result from the presence of large numbers of persons who have previously remained uninfected. It seems reasonable to assume, therefore, that one way to prevent epidemics would be to vaccinate such persons with a potent influenza vaccine containing the appropriate strain.
As regards pandemics, it seems that these could be curtailed only if large quantities of vaccine could be prepared quickly from the new strain and used on a very large scale.
Vaccines
The efficacy of influenza vaccines is not easy to assess by clinical trial because the immunity of the participants can only be known before the trial by antibody estimations, because the exposure to influenza which the participants will experience is bound to be uncertain, and because the symptoms of influenza are readily confused with those due to other viruses. However, taking all the evidence into account it appears that a potent influenza vaccine containing the correct antigenic strain will confer substantial protection (Davenport 1962 ).
The duration of such immunity is uncertain but recent (unpublished) studies by the Medical Research Council's Committee on Influenza and Other Respiratory Virus Vaccines indicate that antibody persists in high titre for at least one year, and probably longer, after vaccination with aqueous vaccine.
Protection from vaccines containing mineral oil adjuvants would be expected to be even more persistent but such vaccines are associated with a :small incidence of troublesome local reactions (Medical Research Council 1964) . It is hoped that new adjuvants without this disadvantage will be developed and the MRC Committee are testing those which show most promise.
Live vaccines have not yet been used in
England on a large scale but several small trials have been made using the Russian Iksha A2 strain. The early results showed a reasonable antibody response to a single dose of vaccine but later trialsmade with batches containing virus which had undergone further passagewere less satisfactory probably owing to changes in the virus after further passage (Medical Research Council 1967) .
Live vaccine, which has the advantage of intranasal administration and possibly of interference with infection by the natural pathogen, is of great potential value in the face of epidemics. However, if live vaccine were to be used to halt pandemics, the speed with which the vaccine could be prepared would be crucial. Unfortunately attenuation of the natural pathogen to a point at which the virus could protect without causing reactions presents serious technical difficulties; it seems probable that many months would elapse before a safe and effective live vaccine could be made available from a new variant.
Indicationsfor Vaccination in Industry
Industrlal medical officers often have to decide whether to vaccinate the employees under their care against influenza. Usually the information available is insufficient to provide much help in making the decision. In particular, there is often little Information about the proportion of the employees likely to be susceptible.
A recent survey by Dr M S Pereira, however, has indicated that a very substantial proportion of the population is probably immune to the current strain (Pereira 1966, personal communication). Such widely based immunity does not seem likely to predispose to widespread outbreaks of influenza. Moreover, many employees offered vaccination would already be immune.
Future Epidemiological Research
Future epidemiological research into influenza should clearly continue to be concerned with the testing of inactivated vaccines prepared with new adjuvants and with trials of new batches of live vaccine. Moreover, there is insufficient information about the prevalence and spread of influenza in the United Kingdom and it is hoped, in cooperation with the Public Health Laboratory Service Laboratories and family doctors, to set up a simple system for observing and recording its occurrence as quickly and accurately as possible. Another need is to continue the antibody studies necessary to determine the proportion of persons in the United Kingdom susceptible to current strains. Finally, more investigation is needed of the relationship of -influenza antibody to immunity.
Sir Christopher Andrewes (Salisbury, Wiltshire), opening the discussion, referred to the major antigenic changes in influenza A viruses which occurred at long intervals and rendered difficult the manufacture of appropriate vaccines. In the United States, T Francis and his colleagues (Francis & Maassab 1965 ) favoured a polyvalent vaccine, on the grounds that influenza A viruses contained a limited number of antigens undergoing cyclical changes. Most other workers preferred vaccines prepared from the most recently isolated strains. There was need for fundamental research into the immunological variants of the influenza viruses. Dr Derek Hobson (Liverpool) discussed some of the laboratory problems which would have to be solved before acceptable live influenza virus vaccines could be developed. There was no satisfactory experimental animal model of the human disease, and no laboratory characteristics of the viruses are known which can be used as indirect markers of the virulence of a given virus strain. Hence, selection of suitably attenuated viruses, and control tests on successive batches of living vaccine to guard against reversion to full virulence or over-attenuation (with lack of immunogenicity for man) must at present be performed on a trial and error basis in human volunteer experiments.
Some preliminary studies were reported on laboratory differences in behaviour between Iksha strains of influenza virus A2 which were known to differ in their clinical infectivity for man. In a successful vaccine pool composed of the sixth egg passage of Iksha virus, the virus was shown to possess hamagglutinin of greater thermolability but weaker eluting activity than a later unsuccessful vaccine pool in which the Iksha strain had undergone one human passage plus two further egg passages. Further experiments suggested that these changes could be shown to breed true as stable laboratory markers of the difference between the early and late vaccine pools. Similar investigations were in progress to determine if these laboratory marker characteristics could be used reliably to assess the degree of infectivity of other influenza virus strains for man.
Dr P B Stones (Sandwich, Kent) drew attention to the time lag between the isolation of a new variant of influenza virus A and the manufacture on a commercial scale of vaccines prepared from the new variant. This would be about six months for inactivated vaccine and from six to twelve months for live attenuated vaccine. The immunogenicity of attenuated strains appeared to vary directly with their reactogenicity.
Meeting October 271966
Alcoholism The following papers were read: Epidemiological Data Concerning Alcoholism: A Review Professor W I M Kessel Epidemiological Research on Symptoms of Abnormal Drinking Dr Griffith Edwards and the staff of the Alcohol Impact Project
